CAJ | 학술논문

目的探讨液泡型ATP合酶(V-ATPase)表达与术后辅助化疗的Ⅱ期结肠癌患者临床病理特征关系及其临床意义.方法分别从复发组和未复发组患者中随机选取30例Ⅱ期结肠癌组织和配对癌旁组织,采用反转录-聚合酶链反应(RT-PCR)和实时定量聚合酶链反应(Real-time PCR)检测V-ATPase基因的mRNA表达量,用免疫组织化学EnVinsion法检测V-ATPase基因在化疗后71例未复发患者和35例复发患者癌组织及相应癌旁正常组织中的蛋白表达量.采用x2检验比较计数资料之间差异,通过COX比例风险模型评估风险.结果复发组和未复发组癌组织中V-ATPase mRNA的平均表达量分别是7.45、2.52 (x2=14.39,P＜0.01).免疫组织化学结果显示V-ATPase在复发和未复发患者癌组织中阳性表达率为分别为94.3％(33/35)、50.7％(36/71)(x2 =19.60,P＜0.01).V-ATPase过表达者术后化疗后5年无瘤生存率和总体生存率均降低.结论 V-ATPase基因是影响Ⅱ期结肠癌术后化疗患者生存率的独立预后因素,可能是评估Ⅱ期结肠癌复发风险的高危因素.
목적 탐토액포형ATP합매(V-ATPase)표체여술후보조화료적Ⅱ기결장암환자림상병리특정관계급기림상의의.방법 분별종복발조화미복발조환자중수궤선취30례Ⅱ기결장암조직화배대암방조직,채용반전록-취합매련반응(RT-PCR)화실시정량취합매련반응(Real-time PCR)검측V-ATPase기인적mRNA표체량,용면역조직화학EnVinsion법검측V-ATPase기인재화료후71례미복발환자화35례복발환자암조직급상응암방정상조직중적단백표체량.채용x2검험비교계수자료지간차이,통과COX비례풍험모형평고풍험.결과 복발조화미복발조암조직중V-ATPase mRNA적평균표체량분별시7.45、2.52 (x2=14.39,P＜0.01).면역조직화학결과현시V-ATPase재복발화미복발환자암조직중양성표체솔위분별위94.3％(33/35)、50.7％(36/71)(x2 =19.60,P＜0.01).V-ATPase과표체자술후화료후5년무류생존솔화총체생존솔균강저.결론 V-ATPase기인시영향Ⅱ기결장암술후화료환자생존솔적독립예후인소,가능시평고Ⅱ기결장암복발풍험적고위인소.
Objective To explore the relationship of clinical pathological featureand itsignificance between vacuole type ATP synthase (V-ATPase) expression and postoperative adjuvanchemotherapy of patientwith stage Ⅱ colon cancer.MethodWe randomly selected 30 patientwith stage Ⅱ colon cancetissueand matched tissueadjacento carcinomrespectively from relapse group and non-relapse group.Real-time quantitative polymerase chain reaction (Real-time PCR) were used to detecthe mRNexpression of V-ATPase.Immunohistochemical EnVinsion method waused to detecthe V-ATPase protein expression in the carcinomand adjacentissue71 patientdid norelapse and 35 relapsed patientaftepostoperative chemotherapy.Chi-square test/Fisher' exactesand Cox proportional hazard model were used to analysis.ResultThe average expression level of V-ATPase mRNin 30 tumorecurrenand non-recurrenpatientof V-ATPase are respectively 7.45, 2.52 (x2 =14.39 P ＜ 0.01).Immunohistochemical resultshowed thathe positive expression rate of V-ATPase in recurrenand non-recurrenpatienttissuewere 94.3％ (33/35), and 50.7％ (36/71) (x2 =19.60, P ＜ 0.01).Patientwith V-ATPase overexpression had poo5-yeadisease-free survival rate and overall survival hazard ratio (HR).Conclusion V-ATPase ian independenprognostifactoaffecting the survival of patientwith stage Ⅱ colon cancepatientreceiving postoperative chemotherapy.